Literature DB >> 21254375

Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors.

Maria Valeria Corrias1, Riccardo Haupt, Barbara Carlini, Enrico Cappelli, Stefano Giardino, Gino Tripodi, Gian Paolo Tonini, Alberto Garaventa, Vito Pistoia, Angela Pistorio.   

Abstract

BACKGROUND: Multiple target molecular monitoring of minimal residual disease in neuroblastoma (NB) patients may increase sensitivity and overcome tumor heterogeneity. However, multiple target analysis is costly and time consuming, thus improvement with respect to single target monitoring needs to be achieved. PROCEDURES: Italian patients with localized NB were evaluated at diagnosis for TH, GD2-s, DDC, DCX, ELAV-4, STX, and Phox2b mRNA expressions. Patients with metastatic NB were tested as positive controls, together with NB primary tumors and cell lines, while healthy donors were tested as negative controls.
RESULTS: All NB-related markers but Phox2b were expressed in healthy donors, and in a high percentage of patients with localized NB without association with clinical events. The introduction of cut-off levels increased marker specificity, although the percentage of positive results was only slightly modified. While TH positivity in PB samples significantly associated with a worse prognosis, a paradox association was found for GD2-s mRNA expression. No correlation and agreement between quantitative and qualitative results obtained with the two assays were found. In the set of samples tested for all markers, no pattern of expression was found to be associated with a specific clinical situation.
CONCLUSION: These findings suggest that positive molecular results may not reflect the presence of disease, and that correlation among different markers is small in condition of low tumor burden. Thus, to reduce cost and amount of precious samples, in addition to TH, whose prognostic value was confirmed, only Phox2b warrants further evaluation in multi-center, prospective studies for high risk patients.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21254375     DOI: 10.1002/pbc.22960

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  10 in total

1.  TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.

Authors:  Yania Yáñez; David Hervás; Elena Grau; Silvestre Oltra; Gema Pérez; Sarai Palanca; Mar Bermúdez; Catalina Márquez; Adela Cañete; Victoria Castel
Journal:  J Cancer Res Clin Oncol       Date:  2015-10-24       Impact factor: 4.553

2.  Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients.

Authors:  Nobuyuki Yamamoto; Aiko Kozaki; Tri Budi Hartomo; Tomoko Yanai; Daiichiro Hasegawa; Keiichiro Kawasaki; Yoshiyuki Kosaka; Masafumi Matsuo; Satoshi Hirase; Takeshi Mori; Akira Hayakawa; Kazumoto Iijima; Hisahide Nishio; Noriyuki Nishimura
Journal:  Oncol Lett       Date:  2015-09-16       Impact factor: 2.967

3.  Early detection of tumor relapse/regrowth by consecutive minimal residual disease monitoring in high-risk neuroblastoma patients.

Authors:  Satoshi Hirase; Atsuro Saitoh; Tri Budi Hartomo; Aiko Kozaki; Tomoko Yanai; Daiichiro Hasegawa; Keiichiro Kawasaki; Yoshiyuki Kosaka; Masafumi Matsuo; Nobuyuki Yamamoto; Takeshi Mori; Akira Hayakawa; Kazumoto Iijima; Hisahide Nishio; Noriyuki Nishimura
Journal:  Oncol Lett       Date:  2016-06-07       Impact factor: 2.967

4.  Deregulation of focal adhesion pathway mediated by miR-659-3p is implicated in bone marrow infiltration of stage M neuroblastoma patients.

Authors:  Sara Stigliani; Paola Scaruffi; Corrado Lagazio; Luca Persico; Barbara Carlini; Luigi Varesio; Fabio Morandi; Martina Morini; Anna Rita Gigliotti; Maria Rosaria Esposito; Elisabetta Viscardi; Valerio Cecinati; Massimo Conte; Maria Valeria Corrias
Journal:  Oncotarget       Date:  2015-05-30

5.  RT-qPCR for PHOX2B mRNA is a highly specific and sensitive method to assess neuroblastoma minimal residual disease in testicular tissue.

Authors:  Victoria Grèze; Justyna Kanold; Fanny Chambon; Pascale Halle; Anne-Sophie Gremeau; Nathalie Rives; Nadège Rouel; Bruno Pereira; Andrei Tchirkov; Florence Brugnon
Journal:  Oncol Lett       Date:  2017-05-24       Impact factor: 2.967

Review 6.  Opportunities and challenges of circulating biomarkers in neuroblastoma.

Authors:  Ricky M Trigg; Jacqui A Shaw; Suzanne D Turner
Journal:  Open Biol       Date:  2019-05-31       Impact factor: 6.411

7.  The Application of and Factors Influencing, the NB5 Assay in Neuroblastomas.

Authors:  Zuopeng Wang; Chengyun Wang; Yibing Xu; Jun Le; Yuan Jiang; Wei Yao; Hongsheng Wang; Kai Li
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

8.  Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma.

Authors:  Na Hee Lee; Meong Hi Son; Young Bae Choi; Eunsang Yi; Ji Won Lee; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo
Journal:  Cancer Res Treat       Date:  2016-03-24       Impact factor: 4.679

9.  PCR-based amplification of circulating RNAs as prognostic and predictive biomarkers - Focus on neuroblastoma.

Authors:  Sam C Brownhill; Sue A Burchill
Journal:  Pract Lab Med       Date:  2016-04-20

10.  miRNA expression profile of bone marrow resident cells from children with neuroblastoma is not significantly different from that of healthy children.

Authors:  Sara Stigliani; Fabio Morandi; Luca Persico; Corrado Lagazio; Giovanni Erminio; Paola Scaruffi; Maria Valeria Corrias
Journal:  Oncotarget       Date:  2018-04-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.